Private Equity can play a large role in growth strategies and exit planning for private companies. But what role does the private company's board - and specifically private directors - play before, during and after Private Equity gains control? Hear from Partners of leading Private Equity firms, Investment Bankers, as well as from Directors and C-level executives of private companies that have been through the process.
This event is designed for private company business owners and management, private equity and venture capital firm management, board members, prospective board members, and those who work directly with private boards.
Key takeaways addressed will be:
What private board characteristics will attract and impress Private Equity or Investment Bankers?
How should a board best evaluate the prospect of a PE or Investment banking partner?
What mistakes should be avoided by the private company board?
What commonly happens to the board after PE takes control?
How does PE gain value from the boards prior to PE involvement? And how do they gain value after the company joins the PE firm's portfolio?
Does any of this differ for "platform" companies vs. "add-on/tuck-in" acquisitions?
How can private directors best position themselves for board opportunities with PE portfolio companies?
Michelle Noon, General Partner Riverside Partners Michael Cassata, Managing Director Consilium Partners Laura Gratten, Managing Director at Thomas H Lee Paul Griffiths, Founding Partner & CEO of MedTouch
Richard Adduci, Esito LLC
Michelle Noon is a General Partner and member of the Firm Management and Investment Committees at Riverside Partners. Michelle leads Technology sector investments for Riverside. Within technology, Michelle leads investments in enterprise and application software, transaction/payment processing, software-based services and media technology. Michelle is involved in all aspects of the deal process including sourcing, due diligence, negotiation and deal execution, as well as portfolio management as she works with her portfolio companies’ management teams to execute on their operational improvement and growth strategies.
Prior to joining Riverside, Michelle was an investment professional in the San Francisco office of private equity firm Thoma Bravo where she focused on software investments.
Michael Cassata, Managing Director Consilium Partners. In his more than 15 years as an investment banker, Mike has worked with a broad range of technology companies, including software, IT technology-enabled business services, healthcare and financial technology, digital media, e-learning and managed services companies. He's developed extensive M&A and private capital raising experience and provides senior-level expertise and counsel to Consilium clients. Mike has worked with a wide range of on-premise and cloud computing companies using both SaaS and perpetual license models, many of which have been involved in data analytics, regulatory compliance, banking technology, electronic health information and mobile applications.
Mike joined Consilium Partners in 2010 through a merger with Adventum Group, a Boston-based middle market investment banking firm he founded in 2000 after a successful career as an entrepreneur. Earlier in his career, he co-founded a healthcare software company that he grew into a market leader before successfully selling it to NASDAQ-listed healthcare information firm. Mike then joined the acquiring company's executive management team, where he helped to grow revenue from $90 million to over $250 million through the acquisition and integration of six companies over 18 months. This aggressive acquisition strategy led to the company sale to one of the largest software firms in the UK for over $900 million in an all-cash transaction.
Laura A. Grattan is a managing director at Thomas H. Lee Partners. Prior to joining Thomas H. Lee Partners, Ms. Grattan worked in the Private Equity Group at Goldman, Sachs & Co. Ms. Grattan is currently a director of Alfresco Software, Inc. and iHeartMedia, Inc. and a board observer at Univision Communications, Inc. Her prior directorships include inVentiv Health, Inc. and West Corporation. Her investment experience at Thomas H. Lee Partners also includes Aramark Corporation, Grub Hub Seamless Holdings Corporation and Warner Chilcott plc. Ms. Grattan's charitable and non-profit activities include serving on the board of Boston Scores and BELL (Building Educated Leaders for Life). Ms. Grattan holds an A.B., summa cum laude, in Economics from Dartmouth College and an M.B.A. from Harvard Business School.
Paul Griffiths is the Founding Partner + CEO of MedTouch. With a 20 year career in building brand-aware, web technology solutions, Paul sets the strategic vision for the company at a time of dramatic industry transformation. Over the last decade, Paul has worked with a variety of clients across the United States, giving him a uniquely national perspective on the challenges of hospitals, integrated delivery networks, and health plans. I
Since 2004, Paul has led MedTouch through periods of constant renewal and adaption. He was named a "40 under 40," by the Boston Business Journal. albeit a few years ago now. Prior to MedTouch, Paul worked with technology-focused startups, including raising over $40m from top tier VC funds. He is a graduate of Harvard Business School and also holds a MA from Boston University in, of all things, Creative Writing.
Rich Adduci is a recognized Digital Innovator and Leader, who currently serves as an Advisor at Esito LLC, a firm he founded to serve the Private Equity and Venture Capital industries. Mr. Adduci’s focus at Esito includes due diligence, M&A transaction support, Technology Advisory Services (Digital, IT, Cybersecurity and Software Product Development), and Sales Channel advisory. Prior to Esito, Mr. Adduci’s experience has included Partner at Accenture, and Global CIO at Boston Scientific and National Grid. Mr. Adduci has helped lead or support more than 22 acquisitions and 8 divestitures / carveouts across a full lifecycle from early due diligence through day one planning, TSA formulation, day 1 execution, and TSA wind down / synergy realization.
Mr. Adduci presently serves on the Board of Directors for ERT, a Clinical Trial software company and as an Advisor to RocketWagon and GreenLight Technologies. Mr. Adduci has also previously served on the Board of Directors for GHX (Global Healthcare Exchange), a LifeScience Supply Chain Services Company. Mr. Adduci’s focus on boards is to provide a point of view and expertise around Technology, Digital, IoT, Digital Health, CyberSecurity and Cloud Migration.